Peripheral administration of antisense oligonucleotides targeting the amyloid-β protein precursor reverses AβPP and LRP-1 overexpression in the aged SAMP8 mouse brain
- PMID: 22179572
- DOI: 10.3233/JAD-2011-111517
Peripheral administration of antisense oligonucleotides targeting the amyloid-β protein precursor reverses AβPP and LRP-1 overexpression in the aged SAMP8 mouse brain
Abstract
The senescence accelerated mouse-prone 8 (SAMP8) mouse model of Alzheimer's disease has a natural mutation leading to age-related increases in the amyloid-β protein precursor (AβPP) and amyloid-β (Aβ) in the brain, memory impairment, and deficits in Aβ removal from the brain. Previous studies show that centrally administered antisense oligonucleotide directed against AβPP can decrease AβPP expression and Aβ production in the brains of aged SAMP8 mice, and improve memory. The same antisense crosses the blood-brain barrier and reverses memory deficits when injected intravenously. Here, we give 6 μg of AβPP or control antisense 3 times over 2 week intervals to 12 month old SAMP8 mice. Object recognition test was done 48 hours later, followed by removal of whole brains for immunoblot analysis of AβPP, low-density lipoprotein-related protein-1 (LRP-1), p-glycoprotein (Pgp), receptor for advanced glycation endproducts (RAGE), or ELISA of soluble Aβ(40). Our results show that AβPP antisense completely reverses a 30% age-associated increase in AβPP signal (p < 0.05 versus untreated 4 month old SAMP8). Soluble Aβ(40) increased with age, but was not reversed by antisense. LRP-1 large and small subunits increased significantly with age (147.7%, p < 0.01 and 123.7%, p < 0.05 respectively), and AβPP antisense completely reversed these increases (p < 0.05). Pgp and RAGE were not significantly altered with age or antisense. Antisense also caused improvements in memory (p < 0.001). Together, these data support the therapeutic potential of AβPP antisense and show a unique association between AβPP and LRP-1 expression in the SAMP8 mouse.
Similar articles
-
Impairments in brain-to-blood transport of amyloid-β and reabsorption of cerebrospinal fluid in an animal model of Alzheimer's disease are reversed by antisense directed against amyloid-β protein precursor.J Alzheimers Dis. 2011;23(4):599-605. doi: 10.3233/JAD-2010-100021. J Alzheimers Dis. 2011. PMID: 21098986
-
Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein.J Pharmacol Exp Ther. 2001 Jun;297(3):1113-21. J Pharmacol Exp Ther. 2001. PMID: 11356936
-
Antisense directed at the Abeta region of APP decreases brain oxidative markers in aged senescence accelerated mice.Brain Res. 2004 Aug 20;1018(1):86-96. doi: 10.1016/j.brainres.2004.05.048. Brain Res. 2004. PMID: 15262209
-
LRP in amyloid-beta production and metabolism.Ann N Y Acad Sci. 2006 Nov;1086:35-53. doi: 10.1196/annals.1377.005. Ann N Y Acad Sci. 2006. PMID: 17185504 Review.
-
Functional roles of amyloid-beta protein precursor and amyloid-beta peptides: evidence from experimental studies.J Alzheimers Dis. 2009;18(2):401-12. doi: 10.3233/JAD-2009-1154. J Alzheimers Dis. 2009. PMID: 19584429 Review.
Cited by
-
In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2.Eur J Hum Genet. 2013 Jul;21(7):769-73. doi: 10.1038/ejhg.2012.261. Epub 2012 Nov 28. Eur J Hum Genet. 2013. PMID: 23188051 Free PMC article.
-
APP dyshomeostasis in the pathogenesis of Alzheimer's disease: implications for current drug targets.Alzheimers Res Ther. 2024 Jun 29;16(1):144. doi: 10.1186/s13195-024-01504-w. Alzheimers Res Ther. 2024. PMID: 38951839 Free PMC article. Review.
-
miRNA-383 and miRNA-384 Suppress Proopiomelanocortin Gene Expression in the Hypothalamus: Effects of Early Life Ethanol Exposure.Neuroendocrinology. 2023;113(8):844-858. doi: 10.1159/000530289. Epub 2023 Mar 22. Neuroendocrinology. 2023. PMID: 36948162 Free PMC article.
-
Antisense Drugs Make Sense for Neurological Diseases.Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:831-852. doi: 10.1146/annurev-pharmtox-010919-023738. Epub 2020 Oct 9. Annu Rev Pharmacol Toxicol. 2021. PMID: 33035446 Free PMC article. Review.
-
Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.Nucleic Acid Ther. 2014 Feb;24(1):69-86. doi: 10.1089/nat.2013.0461. Nucleic Acid Ther. 2014. PMID: 24506781 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous